{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:29:45Z","timestamp":1775255385443,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Teva Branded Pharmaceutical Products"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Reslizumab is a humanized anti\u2013IL-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To predict response and nonresponse to intravenous reslizumab at 52 weeks with an algorithm we developed based on clinical indicators from pivotal clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients aged 18 years and older who met Global Initiative for Asthma 4 or 5 criteria and received intravenous reslizumab (n\u2009=\u2009321) in two trials (www.clinicaltrials.gov identifiers, NCT01287039 and NCT01285323) were selected as the data source. A mathematical model was constructed that was based on change from baseline to 16 weeks in Asthma Control Questionnaire and Asthma Quality of Life Questionnaire scores and FEV1, and number of clinical asthma exacerbations during the year before enrollment and in the first 16 weeks of treatment, and these measures were evaluated for their ability to predict the outcome at 52 weeks: responder, nonresponder, or indeterminate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>The algorithm predicted that 276 patients would be classified as responders; in 248 (89.9%), the prediction was correct. In comparison, 26 patients were predicted to be nonresponders; 50.0% of these predictions were correct. Nineteen patients were classified as indeterminate. The algorithm had 95.4\u201395.5% sensitivity and 40.6\u201354.1% specificity. Jackknife and cross-study validation confirmed the robustness of the algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our algorithm enabled prediction at 16 weeks of treatment of the response to intravenous reslizumab treatment at 52 weeks, but it was not suitable for predicting nonresponse. A positive score at 16 weeks should encourage continued treatment, and a negative score should prompt close monitoring to determine whether discontinuation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201708-1668oc","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T16:31:16Z","timestamp":1540225876000},"page":"489-495","source":"Crossref","is-referenced-by-count":21,"title":["Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma"],"prefix":"10.1093","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5064-5849","authenticated-orcid":false,"given":"Eric D.","family":"Bateman","sequence":"first","affiliation":[{"name":"University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratko","family":"Djukanovi\u0107","sequence":"additional","affiliation":[{"name":"Southampton University Hospital, Southampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Castro","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St. Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Canvin","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals Europe BV, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Germinaro","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals, Frazer, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Noble","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals, Frazer, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Garin","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals, Frazer, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Buhl","sequence":"additional","affiliation":[{"name":"Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"2026030321252263600_bib1","doi-asserted-by":"crossref","first-page":"00024","DOI":"10.1183\/23120541.00024-2015","article-title":"Management of the patient with eosinophilic asthma: a new era begins","volume":"1","author":"de Groot","year":"2015","journal-title":"ERJ Open Res"},{"key":"2026030321252263600_bib2","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/cea.12762","article-title":"Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils","volume":"46","author":"Walsh","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"2026030321252263600_bib3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/thx.2009.126722","article-title":"Effects of steroid therapy on inflammatory cell subtypes in asthma","volume":"65","author":"Cowan","year":"2010","journal-title":"Thorax"},{"key":"2026030321252263600_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4065\/84.8.707","article-title":"Managing asthma in primary care: putting new guideline recommendations into context","volume":"84","author":"Wechsler","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2026030321252263600_bib5","first-page":"1586","article-title":"Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions","volume":"6","author":"Overington","year":"2014","journal-title":"J Thorac Dis"},{"key":"2026030321252263600_bib6","article-title":"Global Initiative for Asthma (GINA) report, 2017: the global strategy for asthma management and prevention","author":"Global Initiative for Asthma (GINA)"},{"key":"2026030321252263600_bib7","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"2026030321252263600_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026030321252263600_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pupt.2017.01.011","article-title":"Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils","volume":"43","author":"Brusselle","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"2026030321252263600_bib10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/TCRM.S1382","article-title":"New approaches to managing asthma: a US perspective","volume":"4","author":"Berger","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"2026030321252263600_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1183\/16000617.00009014","article-title":"Clinically relevant subgroups in COPD and asthma","volume":"24","author":"Turner","year":"2015","journal-title":"Eur Respir Rev"},{"key":"2026030321252263600_bib12","doi-asserted-by":"crossref","first-page":"e0143793","DOI":"10.1371\/journal.pone.0143793","article-title":"Prediction of long-term benefits of inhaled steroids by phenotypic markers in moderate-to-severe COPD: a randomized controlled trial","volume":"10","author":"Snoeck-Stroband","year":"2015","journal-title":"PLoS One"},{"key":"2026030321252263600_bib13","doi-asserted-by":"crossref","first-page":"P3483","DOI":"10.1183\/13993003\/erj.44.Suppl_58.P3483","article-title":"Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: a pooled analysis [abstract]","volume":"44","author":"Bousquet","year":"2014","journal-title":"Eur Respir J"},{"key":"2026030321252263600_bib14","doi-asserted-by":"crossref","first-page":"1700634","DOI":"10.1183\/13993003.00634-2017","article-title":"Severe eosinophilic asthma: a roadmap to consensus","volume":"49","author":"Buhl","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030321252263600_bib15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40265-016-0583-2","article-title":"Reslizumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"2026030321252263600_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/JAA.S94164","article-title":"Reslizumab in the management of poorly controlled asthma: the data so far","volume":"9","author":"Maselli","year":"2016","journal-title":"J Asthma Allergy"},{"key":"2026030321252263600_bib17","article-title":"CINQAERO: EPAR \u2013 product information","author":"European Medicines Agency"},{"key":"2026030321252263600_bib18","article-title":"CINQAIR prescribing information","author":"Teva Respiratory LLC"},{"key":"2026030321252263600_bib19","first-page":"OA2998","article-title":"Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients [abstract]","volume":"48","author":"Canvin","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030321252263600_bib20","first-page":"A7782","article-title":"Association between early improvements in lung function and asthma control with reslizumab and the annual rate of asthma exacerbations [abstract]","volume":"193","author":"Bateman","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321252263600_bib21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.rmed.2009.03.008","article-title":"The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update","volume":"103","author":"Holgate","year":"2009","journal-title":"Respir Med"},{"key":"2026030321252263600_bib22","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.jaci.2014.08.015","article-title":"Development and validation of a novel risk score for asthma exacerbations: the risk score for exacerbations","volume":"135","author":"Bateman","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2026030321252263600_bib23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201207-1299OC","article-title":"Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population","volume":"186","author":"Lange","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321252263600_bib24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/thoraxjnl-2013-203270","article-title":"GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway","volume":"68","author":"Leivseth","year":"2013","journal-title":"Thorax"},{"key":"2026030321252263600_bib25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.38304","article-title":"Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression","volume":"66","author":"Baker","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026030321252263600_bib26","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jaip.2017.11.026","article-title":"Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma","volume":"6","author":"Gunsoy","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026030321252263600_bib27","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"2026030321252263600_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","article-title":"Determining a minimal important change in a disease-specific Quality of Life Questionnaire","volume":"47","author":"Juniper","year":"1994","journal-title":"J Clin Epidemiol"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/199\/4\/489\/67182103\/ajrccm_199_4_489.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/199\/4\/489\/67182103\/ajrccm_199_4_489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:08:43Z","timestamp":1775250523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/199\/4\/489\/8497809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,2,15]]},"published-print":{"date-parts":[[2019,2,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201708-1668oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2]]}}}